Century Therapeutics, Inc. Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One
Century Therapeutics, Inc. (IPSC) had Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One of $70.07 million as of 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Notes › Debt and Equity Securities › Debt Securities, Available-for-Sale, Maturity, Allocated and Single Maturity Date, Fair Value
us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue · last filed 2026-08-12
- 2026-06-30: Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One $70.07M.
- 2026-03-31: Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One $83.75M.
- 2025-12-31: Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One $55.26M.
- 2025-09-30: Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One $77.23M.
| Period end | Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One |
|---|---|
| 2026-06-30 | $70.07M 10-Q · filed 2026-08-12 |
| 2026-03-31 | $83.75M 10-Q · filed 2026-05-13 |
| 2025-12-31 | $55.26M 10-Q · filed 2026-08-12 |
| 2025-09-30 | $77.23M 10-Q · filed 2025-11-13 |
| 2025-06-30 | $98.97M 10-Q · filed 2025-08-14 |
| 2025-03-31 | $113.26M 10-Q · filed 2025-05-15 |
| 2024-12-31 | $130.85M 10-K · filed 2026-03-12 |
| 2024-09-30 | $145.52M 10-Q · filed 2024-11-05 |
| 2024-06-30 | $154.94M 10-Q · filed 2024-08-08 |
| 2024-03-31 | $145.20M 10-Q · filed 2024-05-09 |
| 2023-12-31 | $125.41M 10-K · filed 2025-03-19 |
| 2023-09-30 | $114.76M 10-Q · filed 2023-11-09 |
| 2023-06-30 | $92.19M 10-Q · filed 2023-08-09 |
| 2023-03-31 | $164.64M 10-Q · filed 2023-05-11 |
| 2022-12-31 | $231.22M 10-K · filed 2024-03-14 |
| 2022-09-30 | $244.51M 10-Q · filed 2022-11-10 |
| 2022-06-30 | $265.97M 10-Q · filed 2022-08-11 |
| 2022-03-31 | $234.98M 10-Q · filed 2022-05-16 |
| 2021-12-31 | $166.43M 10-K · filed 2023-03-16 |
| 2021-09-30 | $193.86M 10-Q · filed 2021-11-10 |
| 2021-06-30 | $125.29M 10-Q · filed 2021-08-12 |
| 2020-12-31 | $48.54M 10-K · filed 2022-03-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |